Replies to post #38023 on Entest Group Inc

[JokersWild12]

Sweet news. They are VERY optimistic about NR2F6 for human(RGBP) and animal(ENTB) use and see high value with it and expect large company interest.

Nice to see the potential valuation for human immune-oncology deals for development biotechs that can exceed $1 billion+. They have potential beyond that with treating auto-immune disease meaning more $$$ in the valuation. Both of which apply to ENTB. NR2F6 success translates to $$$$ for ENTB.

They also mentioned they have been approached by numerous companies already. Obviously they believe that the value can be increased multi-fold with further optimization of NR2F6 which they plan on.

2017. ENTB low float. $$$$. All IMO.